Tressa Bolton
Nurse Practitioner · Montgomery, ALNPI 1306376694
Payments from drug & device makers
Across 114 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$323
- Amgen$275
- AstraZeneca$274
- Lilly USA, LLC$191
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$188
- Otsuka America Pharmaceutical, Inc.$168
- plus $701 from 12 others
What the payments were for
- Food & beverage$2,120100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $323 |
| Amgen | 15 | $275 |
| AstraZeneca | 14 | $274 |
| Lilly USA, LLC | 10 | $191 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $188 |
| Otsuka America Pharmaceutical, Inc. | 7 | $168 |
| Pfizer | 8 | $134 |
| Neurocrine Biosciences, Inc. | 6 | $123 |
| Atland Pharmaceuticals, LLC | 1 | $76 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $72 |
| Abbott | 3 | $63 |
| Lundbeck LLC | 3 | $62 |
| Dexcom, Inc. | 2 | $41 |
| Exact Sciences | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 1 | $32 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 2 | $22 |
| Esperion Therapeutics, Inc. | 1 | $15 |
How this compares
$2,120 in reported general payments places this provider in the 80th percentile of 1,505 nurse practitioner providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 33 | $31,136 |
| OzempicSemaglutide | 21 | $27,220 |
| EliquisApixaban | 15 | $19,566 |
| LinzessLinaclotide | 34 | $16,903 |
| MounjaroTirzepatide | 16 | $16,300 |
| TrulicityDulaglutide | 14 | $13,866 |
| XareltoRivaroxaban | 12 | $10,459 |
| Celecoxib | 13 | $1,183 |
| Losartan Potassium | 63 | $1,127 |
| Levothyroxine Sodium | 140 | $1,058 |
| Amlodipine Besylate | 84 | $899 |
| Duloxetine Hcl | 39 | $751 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $733 |
| Atorvastatin Calcium | 74 | $697 |
| Rosuvastatin Calcium | 51 | $683 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $191 | $30,67141 claims |
| Novo NordiskOzempic | $323 | $27,22021 claims |
| PfizerEliquis | $134 | $19,56615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,505 nurse practitioner providers in Alabama.
Other nurse practitioner in Montgomery
- Audrey MorganMontgomery$24K
- Ashley HodgensMontgomery$19K
- Kellie BagiMontgomery$14K
- Jessica AdairMontgomery$14K
- Taylor LemkeMontgomery$9K
- Joanne MackinMontgomery$8K
- Kristi SpringerMontgomery$8K
- Erin TannerAlabaster$141K
- Ardie Pack MabienMobile$126K
- Ginger McDanielBirmingham$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.